JPWO2021226148A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021226148A5 JPWO2021226148A5 JP2022567526A JP2022567526A JPWO2021226148A5 JP WO2021226148 A5 JPWO2021226148 A5 JP WO2021226148A5 JP 2022567526 A JP2022567526 A JP 2022567526A JP 2022567526 A JP2022567526 A JP 2022567526A JP WO2021226148 A5 JPWO2021226148 A5 JP WO2021226148A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- body weight
- once
- days
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000037396 body weight Effects 0.000 claims description 75
- 206010028980 Neoplasm Diseases 0.000 claims description 52
- 201000011510 cancer Diseases 0.000 claims description 44
- YHTTWXCDIRTOQX-FQJIPJFPSA-N (6S,9S,15S,18R,23R,26S,29S)-18-amino-6-(4-aminobutyl)-9,26-bis(carboxymethyl)-15-[3-(diaminomethylideneamino)propyl]-2,5,8,11,14,17,25,28-octaoxo-20,21-dithia-1,4,7,10,13,16,24,27-octazabicyclo[27.3.0]dotriacontane-23-carboxylic acid Chemical compound NCCCC[C@@H]1NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]2CCCN2C(=O)CNC1=O)C(O)=O YHTTWXCDIRTOQX-FQJIPJFPSA-N 0.000 claims description 43
- 238000011282 treatment Methods 0.000 claims description 38
- 239000000203 mixture Substances 0.000 claims description 36
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 25
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 25
- 201000002528 pancreatic cancer Diseases 0.000 claims description 25
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 25
- 239000002246 antineoplastic agent Substances 0.000 claims description 14
- 239000008366 buffered solution Substances 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 229960001592 paclitaxel Drugs 0.000 claims description 10
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 10
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 claims description 8
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 8
- 229960005277 gemcitabine Drugs 0.000 claims description 8
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 8
- 229920001184 polypeptide Polymers 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 201000007270 liver cancer Diseases 0.000 claims description 6
- 208000014018 liver neoplasm Diseases 0.000 claims description 6
- 230000004083 survival effect Effects 0.000 claims description 6
- 239000003053 toxin Substances 0.000 claims description 6
- 231100000765 toxin Toxicity 0.000 claims description 6
- 230000001394 metastastic effect Effects 0.000 claims description 5
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 5
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims description 4
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 4
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- -1 antibody Substances 0.000 claims description 4
- 229940041181 antineoplastic drug Drugs 0.000 claims description 4
- 238000002512 chemotherapy Methods 0.000 claims description 4
- 231100000433 cytotoxic Toxicity 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 230000001472 cytotoxic effect Effects 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 201000010985 invasive ductal carcinoma Diseases 0.000 claims description 4
- 239000002609 medium Substances 0.000 claims description 4
- 229960005558 mertansine Drugs 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 229960000575 trastuzumab Drugs 0.000 claims description 4
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims description 4
- 102000004400 Aminopeptidases Human genes 0.000 claims description 2
- 108090000915 Aminopeptidases Proteins 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 2
- 102000005367 Carboxypeptidases Human genes 0.000 claims description 2
- 108010006303 Carboxypeptidases Proteins 0.000 claims description 2
- 102000004091 Caspase-8 Human genes 0.000 claims description 2
- 108090000538 Caspase-8 Proteins 0.000 claims description 2
- 102000011727 Caspases Human genes 0.000 claims description 2
- 108010076667 Caspases Proteins 0.000 claims description 2
- 102000053642 Catalytic RNA Human genes 0.000 claims description 2
- 108090000994 Catalytic RNA Proteins 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 102000009016 Cholera Toxin Human genes 0.000 claims description 2
- 108010049048 Cholera Toxin Proteins 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 claims description 2
- 208000002699 Digestive System Neoplasms Diseases 0.000 claims description 2
- 101800000585 Diphtheria toxin fragment A Proteins 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 102000009465 Growth Factor Receptors Human genes 0.000 claims description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 claims description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- 108091034117 Oligonucleotide Proteins 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 102000035195 Peptidases Human genes 0.000 claims description 2
- 108091005804 Peptidases Proteins 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 239000004365 Protease Substances 0.000 claims description 2
- 241000589516 Pseudomonas Species 0.000 claims description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 108010039491 Ricin Proteins 0.000 claims description 2
- 235000004443 Ricinus communis Nutrition 0.000 claims description 2
- 240000000528 Ricinus communis Species 0.000 claims description 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims description 2
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 2
- 229940123237 Taxane Drugs 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 108700019146 Transgenes Proteins 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 229940122803 Vinca alkaloid Drugs 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 206010047741 Vulval cancer Diseases 0.000 claims description 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 229940009456 adriamycin Drugs 0.000 claims description 2
- 229940100198 alkylating agent Drugs 0.000 claims description 2
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 230000001772 anti-angiogenic effect Effects 0.000 claims description 2
- 230000000340 anti-metabolite Effects 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 239000000611 antibody drug conjugate Substances 0.000 claims description 2
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 2
- 229940100197 antimetabolite Drugs 0.000 claims description 2
- 239000002256 antimetabolite Substances 0.000 claims description 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 2
- 239000012736 aqueous medium Substances 0.000 claims description 2
- 229960003852 atezolizumab Drugs 0.000 claims description 2
- 229950002916 avelumab Drugs 0.000 claims description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 2
- 239000007975 buffered saline Substances 0.000 claims description 2
- 229960004562 carboplatin Drugs 0.000 claims description 2
- 229960000419 catumaxomab Drugs 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 238000002659 cell therapy Methods 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 2
- 208000024558 digestive system cancer Diseases 0.000 claims description 2
- 229960003668 docetaxel Drugs 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229950009791 durvalumab Drugs 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 229940116977 epidermal growth factor Drugs 0.000 claims description 2
- 230000029142 excretion Effects 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 230000004927 fusion Effects 0.000 claims description 2
- 201000010231 gastrointestinal system cancer Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 229960005540 iRGD Drugs 0.000 claims description 2
- 229960001101 ifosfamide Drugs 0.000 claims description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 229960005386 ipilimumab Drugs 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 210000002540 macrophage Anatomy 0.000 claims description 2
- ANZJBCHSOXCCRQ-FKUXLPTCSA-N mertansine Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCS)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ANZJBCHSOXCCRQ-FKUXLPTCSA-N 0.000 claims description 2
- 108020004999 messenger RNA Proteins 0.000 claims description 2
- 230000004060 metabolic process Effects 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 210000000822 natural killer cell Anatomy 0.000 claims description 2
- 229960003301 nivolumab Drugs 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 239000002777 nucleoside Substances 0.000 claims description 2
- 125000003835 nucleoside group Chemical group 0.000 claims description 2
- 229960002621 pembrolizumab Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229910052697 platinum Inorganic materials 0.000 claims description 2
- 230000000861 pro-apoptotic effect Effects 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 108091092562 ribozyme Proteins 0.000 claims description 2
- 229940095743 selective estrogen receptor modulator Drugs 0.000 claims description 2
- 239000000333 selective estrogen receptor modulator Substances 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 235000000346 sugar Nutrition 0.000 claims description 2
- 150000008163 sugars Chemical class 0.000 claims description 2
- 229920001059 synthetic polymer Polymers 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 201000005102 vulva cancer Diseases 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 238000011394 anticancer treatment Methods 0.000 claims 2
- 238000000034 method Methods 0.000 description 29
- 238000011319 anticancer therapy Methods 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063019799P | 2020-05-04 | 2020-05-04 | |
| US63/019,799 | 2020-05-04 | ||
| PCT/US2021/030740 WO2021226148A1 (en) | 2020-05-04 | 2021-05-04 | Methods for treating pancreatic cancer and other solid tumors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023525048A JP2023525048A (ja) | 2023-06-14 |
| JPWO2021226148A5 true JPWO2021226148A5 (pt) | 2024-03-15 |
Family
ID=78468394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022567526A Pending JP2023525048A (ja) | 2020-05-04 | 2021-05-04 | 膵臓がんおよび他の固形腫瘍を処置するための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230201303A1 (pt) |
| EP (1) | EP4146274A4 (pt) |
| JP (1) | JP2023525048A (pt) |
| KR (1) | KR20230006540A (pt) |
| CN (1) | CN115867317A (pt) |
| AU (1) | AU2021266721A1 (pt) |
| CA (1) | CA3182546A1 (pt) |
| WO (1) | WO2021226148A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022235852A1 (en) * | 2021-05-04 | 2022-11-10 | Cend Therapeutics, Inc. | Irgd-analogs and related therapeutic methods |
| CN115212299A (zh) * | 2022-06-21 | 2022-10-21 | 深圳先进技术研究院 | Car-t和car-m联用在制备抗肿瘤药物中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI1015424B1 (pt) * | 2009-06-22 | 2022-01-18 | Burnham Institute For Medical Research | Composição compreendendo um elemento cendr e uma co-composição e composição para uso no reforço da internalização, penetração, ou ambas, de uma co-composição |
| WO2013019945A2 (en) * | 2011-08-02 | 2013-02-07 | Clovis Oncology, Inc.. | Method for selection of chemotherapeutic agents for adenocarcinoma cancer |
| CN102600489A (zh) * | 2012-02-24 | 2012-07-25 | 南方医科大学南方医院 | 含iRGD序列的多肽放射性药物 |
| FR2988721B1 (fr) * | 2012-03-27 | 2014-04-04 | Centre Nat Rech Scient | Nanoparticules de silicium poreux fonctionnalisees et leurs utilisations en therapie photodynamique |
| US9789193B2 (en) * | 2012-06-15 | 2017-10-17 | The Brigham And Women's Hospital, Inc. | Compositions for treating cancer and methods for making the same |
| US20180064662A1 (en) * | 2015-03-05 | 2018-03-08 | The General Hospital Corporation | Novel compositions and uses of metformin agents |
| CA3010711A1 (en) * | 2016-01-08 | 2017-07-13 | The Regents Of The University Of California | Mesoporous silica nanoparticles with lipid bilayer coating for cargo delivery |
| WO2018213631A1 (en) * | 2017-05-18 | 2018-11-22 | The Regents Of The University Of California | Nano-enabled immunotherapy in cancer |
| KR20210142663A (ko) * | 2019-03-08 | 2021-11-25 | 센드 테라퓨틱스 인코포레이티드 | 암을 치료하기 위하여 iRGD와 공동 투여되는 저용량 사이토카인 |
-
2021
- 2021-05-04 AU AU2021266721A patent/AU2021266721A1/en active Pending
- 2021-05-04 WO PCT/US2021/030740 patent/WO2021226148A1/en unknown
- 2021-05-04 CA CA3182546A patent/CA3182546A1/en active Pending
- 2021-05-04 EP EP21800516.3A patent/EP4146274A4/en active Pending
- 2021-05-04 KR KR1020227041792A patent/KR20230006540A/ko active Search and Examination
- 2021-05-04 CN CN202180046526.1A patent/CN115867317A/zh active Pending
- 2021-05-04 US US17/923,408 patent/US20230201303A1/en active Pending
- 2021-05-04 JP JP2022567526A patent/JP2023525048A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Cancer targeted therapeutics: From molecules to drug delivery vehicles | |
| Lutz | Targeting the folate receptor for the treatment of ovarian cancer | |
| JP2015514113A (ja) | 単一特異性および二重特異性抗ｉｇｆ−１ｒおよび抗ｅｒｂｂ３抗体の用法および用量 | |
| WO2020151759A1 (zh) | 治疗肿瘤的联用药物组合物 | |
| KR20180123214A (ko) | Her2 양성 전이성 유방암의 치료를 위한 조성물 및 방법 | |
| CN104997808A (zh) | 用于治疗癌症的方法和组合物 | |
| Yuan et al. | Current and emerging therapies for primary central nervous system lymphoma | |
| JP2021534094A (ja) | 未分化リンパ腫キナーゼ阻害剤と組み合わせてｅｇｆ／ｅｇｆｒ経路を抑制するための方法および組成物 | |
| JP2024075639A (ja) | Ｌｉｖ１－ａｄｃ及び化学療法剤を用いた併用療法 | |
| JP2020506945A (ja) | がんの治療のための方法、組成物及びキット | |
| JP2021073203A (ja) | Ｈｅｒ２陽性転移性乳癌の治療方法 | |
| Abdelbaky et al. | Cancer immunotherapy from biology to nanomedicine | |
| US20210388090A1 (en) | Method and medicament for treating cancer unresponsive to pd-1/pd-l1 signaling inhibitor | |
| JP2023525048A (ja) | 膵臓がんおよび他の固形腫瘍を処置するための方法 | |
| Smith et al. | Pertuzumab for the treatment of patients with previously untreated HER2-positive metastatic breast cancer | |
| Xing et al. | Advances in targeted therapy for pancreatic cancer | |
| JP7240512B2 (ja) | Ｐｄ－１阻害剤を投与することにより子宮頸がんを処置する方法 | |
| JPWO2021226148A5 (pt) | ||
| KR20240023592A (ko) | 삼중 병용 요법 | |
| JP2023549698A (ja) | がんの治療のためのナノ粒子の組成物 | |
| Kirti et al. | Nanoparticle-mediated metronomic chemotherapy in cancer: A paradigm of precision and persistence | |
| TWI671072B (zh) | 曲氟尿苷(trifluridine)/替匹拉希(tipiracil)鹽酸鹽、抗腫瘤鉑錯合物及免疫檢查點調節子之間的新穎組合 | |
| De et al. | Recent advancements in immunotherapy for colorectal cancer | |
| Cheng et al. | Combined Docetaxel/Pictilisib-Loaded mPEGylated Nanocarriers with Dual HER2 Targeting Antibodies for Synergistic Chemotherapy of Breast Cancer | |
| CN107126563B (zh) | 含低剂量阻断vegf信号通路的抗体的组合物及其用途 |